SAMD9 and Bone marrow hypocellularity: In 2016, Narumi et al., reported on heterozygous gain-of-function mutations in SAMD9 in 11 patients with growth restriction apparent from fetal life, adrenal insufficiency, and gonadal failure, together with bone marrow failure [3].